R&D channel feed

Geor­gia sen­a­tor urges ma­jor­i­ty leader Chuck Schumer to fol­low through on in­sulin cap leg­is­la­tion

4 years ago

Aim­ing to jump ahead of Big Phar­ma heavy­weights, Seres moves to fi­nal­ize C. dif­fi­cile FDA pitch

4 years ago

Lil­ly un­veils ear­ly long-term da­ta on eczema drug that could chip away at Dupix­ent mar­ket

4 years ago

Ac­tivist in­vestors at­tempt to change the course at Ra­dius Health, six months af­ter two dis­ap­point­ing read­outs

4 years ago
People

Covid-19 roundup: Mer­ck, Ridge­back drop new analy­ses for mol­nupi­ravir; Veru sub­mits EUA for an­tivi­ral treat­ment

4 years ago
Coronavirus

DC ap­peals court quash­es Nos­trum's suit against FDA, ex­plain­ing CRLs are not fi­nal re­jec­tions

4 years ago
FDA+

#AS­CO22: Play­ing catch-up with Lumakras: Mi­rati touts CNS-spe­cif­ic ac­tiv­i­ty that an­a­lysts think pad the case for ap­proval

4 years ago

#AS­CO22: Ear­ly stock win­ner Adicet re­ports CRs for their off-the-shelf gam­ma delta CAR-T

4 years ago

Prax­is nose­dives as an­ti­de­pres­sant ef­fort col­laps­es in PhII/III fail — lay­offs to fol­low

4 years ago

Amarin CFO re­signs amid cost-cut­ting mea­sures, staff re­duc­tion of 40%

4 years ago
People

#AS­CO22: As it dodges a takeover bid, Zymeworks wants what Dai­ichi Sankyo got: a mas­sive Big Phar­ma part­ner

4 years ago

#AS­CO2022 roundup: CG On­col­o­gy builds on head-turn­ing com­bo da­ta; EQRx doesn’t have a way in­to US mar­kets

4 years ago

FDA ap­proves GSK's MMR vac­cine, the first new green light in more than half a cen­tu­ry

4 years ago
FDA+

#AS­CO22: Rare bio­mark­er leads to ‘un­prece­dent­ed’ re­sults in small rec­tal can­cer study

4 years ago

#AS­CO22: BioN­Tech says mR­NA vac­cine safe in 15 of 16 pa­tients with dead­ly pan­cre­at­ic can­cer

4 years ago

#AS­CO22: In yet an­oth­er sting­ing set­back, Pfiz­er’s block­buster CDK 4/6 fails its lat­est test on sur­vival. But can No­var­tis and Eli Lil­ly ben­e­fit?

4 years ago

#AS­CO22: Merus looks to beat El­e­va­tion to NRG1+ sum­mit as BLA fil­ing ap­proach­es

4 years ago

#AS­CO22: En­her­tu blows chemother­a­py out of the wa­ter, re­defin­ing breast can­cer sub­groups along the way

4 years ago

#AS­CO22: Fol­low­ing back-to-back TIG­IT bombs, Roche of­fers in­sight in­to first PhI­II tri­al fail

4 years ago

#AS­CO22: Leg­end, J&J say Carvyk­ti holds up past the two-year mark as pair preps for po­ten­tial sec­ond nod

4 years ago
China
Cell/Gene Tx

#AS­CO22: Gilead’s Trodelvy shows slim ben­e­fit in com­mon form of breast can­cer

4 years ago

#AS­CO22: With me­di­an dura­bil­i­ty da­ta, Cul­li­nan aims to 'dis­tin­guish it­self' from Takeda's Exkiv­i­ty and J&J's Ry­bre­vant in ex­on 20 NSCLC

4 years ago

#AS­CO22: Un­con­cerned with lat­er mar­ket en­try, Ar­cel­lx on the up with new BC­MA CAR-T da­ta

4 years ago

Can wear­ables help Parkin­son's pa­tients? Ver­i­ly pub­lish­es new da­ta from vir­tu­al ex­ams

4 years ago
Pharma
First page Previous page 132133134135136137138 Next page Last page
A service from the Financial Times